文献速递前列腺癌

循环免疫与癌症驱动基因生物标志物可提前十余年预警前列腺癌诊断

Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10 yr.
PubMed 文献 · Eur Urol · 2026-10-22

基于EPIC队列的病例-队列研究,对982例前列腺癌病例和1573名亚队列成员基线血浆用SomaScan 7k平台检测超6000种蛋白。部分蛋白在ARIC研究中一致,并获得孟德尔随机化和外显子基因负荷分析支持。

要点

  • ACP3、FLT4、KLK3与总体前列腺癌风险正相关,KLK3效应最强。
  • ANKRD1与侵袭性前列腺癌风险相关,且在多个临床相关亚型中一致。

核心结论

  • 前瞻性血浆蛋白组学分析发现多种循环蛋白与未来前列腺癌风险相关,涉及免疫、黏附、血管生成和前列腺癌驱动基因通路。
  • 这些蛋白可作为总体和临床显著前列腺癌的候选蛋白风险因素,需进一步验证和机制评估。

研究设计与样本

  • 在欧洲癌症与营养前瞻性调查(EPIC)内开展病例-队列研究,纳入982例新发前列腺癌病例和1573名亚队列参与者。
  • 使用SomaScan 7k平台检测基线血浆中超过6000种蛋白,采用Prentice加权Cox模型估计关联。
  • 共同主要终点为总体前列腺癌和侵袭性前列腺癌(n=290),结果在ARIC研究中评估,并辅以孟德尔随机化和外显子基因负荷分析。

主要发现

  • 7种蛋白与侵袭性前列腺癌风险相关,其中ANKRD1在多个临床相关疾病亚型中一致相关。
  • ACP3、ANXA2、APOC2和KLK3在EPIC和ARIC中均显示一致关联;4种蛋白获孟德尔随机化分析支持,8种获罕见变异负荷检验支持。
  • ERBB3、KRAS和NRAS等已知前列腺癌驱动基因的循环产物与未来侵袭性疾病相关。

临床怎么用

  • 这些循环蛋白标志物有潜力用于前列腺癌风险分层和早期预警,但尚未达到临床常规应用标准。
  • KLK3(PSA)的强关联支持其作为风险标志物的既有地位,其他蛋白可作为补充候选。
  • 驱动基因相关循环蛋白(如ERBB3、KRAS、NRAS产物)可能为侵袭性疾病预警提供新方向。

局限性

  • 外部重复验证不完整。
  • 不同队列间终点数据可及性存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Prospective proteomic and proteogenomic studies may enhance the understanding of proteins associated with prostate cancer (PCa) development. METHODS: In a case-cohort study within the European Prospective Investigation into Cancer and Nutrition (EPIC), baseline plasma samples from 982 incident PCa cases and 1573 subcohort participants were profiled using the SomaScan 7k platform (over 6000 proteins). Associations were estimated using Prentice-weighted Cox models. The coprimary end points were incident overall PCa and aggressive PCa (n = 290). Findings were evaluated in the Atherosclerosis Risk in Communities (ARIC) study and supported by Mendelian randomization (MR) and exome gene-burden analyses. KEY FINDINGS AND LIMITATIONS: ACP3, FLT4, and KLK3 were associated with overall PCa risk (hazard ratio [HR] per 1 standard deviation [SD] increase were 1.20 [1.10-1.31], 1.26 [1.13-1.40], and 2.28 [1.96-2.65], respectively). Seven proteins were associated with aggressive PCa risk, with ANKRD1 consistently associated across multiple clinically relevant disease subtypes. Twelve proteins were associated with PCa diagnosed >15 yr after blood draw, including ANXA2, GZMK, and OSCAR. ACP3, ANXA2, APOC2, and KLK3 showed consistent associations in both EPIC and ARIC. Additionally, four proteins had support from MR analyses and eight from rare-variant burden tests. Circulating products of established PCa driver genes, including ERBB3, KRAS, and NRAS, were associated with future aggressive disease. Limitations include incomplete external replication and differences in end point availability across cohorts. CONCLUSIONS AND CLINICAL IMPLICATIONS: Prospective plasma proteomic analyses identified circulating proteins associated with future PCa risk, including proteins related to immune, adhesion, angiogenesis, and PCa driver-gene pathways. These findings identify candidate protein risk factors for overall and clinically significant PCa, and warrant further validation and mechanistic evaluation.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Huang Z, Parsaeian M, Viallon V, et al. Circulating Immune and Cancer Driver Gene Biomarkers Precede Prostate Cancer Diagnosis by over 10 yr. Eur Urol. 2026. PMID: 42907294. doi:10.1016/j.eururo.2026.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。